Pipeline

Aduro’s extensive pipeline of diverse product candidates builds from three proprietary technology platforms (Live, Attenuated Double-Deleted Listeria (LADD®), STING Pathway Activators, and B-select monoclonal antibodies) to create immunotherapies targeting a variety of cancers, as well as infectious and autoimmune diseases.

LADD Programs

CRS-207 (planned)

2nd line Mesothelioma
antiPD-1
     

CRS-207 (planned)

Gastric
antiPD-1
     

CRS-207

Ovarian
antiPD-1/Epi
     

ADU-741

Prostate
 
     

ADU-214

Lung
 
     

pLADD (planned)

Gastro-intestinal
 
     
Indication
Combination

STING Pathway Programs

ADU-S100

Multiple tumors
 
     

ADU-S100 (planned)

Multiple tumors
antiPD-1
     

Adjuvant

Infectious Disease
 
     

STING-Blok

Autoimmune
 
     
Indication
Combination

B-select Programs

Anti-APRIL (planned)

Multiple Myeloma
 
     

Anti-CD27 agonist

Oncology
 
     

Anti-CTLA4

Oncology
 
     

Anti-PD1

Oncology
 
     

Bispecific Ab

Oncology
 
     
Indication
Combination